Association of PSA level with thiols content in patients with prostate carcinoma

MASAŘÍK, Michal, Jiří SOCHOR, Ondřej ZÍTKA, David HYNEK, Soňa KŘÍŽKOVÁ, Marie STIBOROVÁ, Tomáš ECKSCHLAGER, Vojtěch ADAM and René KIZEK. Association of PSA level with thiols content in patients with prostate carcinoma. In 15th International Symposium on Molecular Medicine. 2012. ISSN 1107-3756.

Basic information

• Original name: Association of PSA level with thiols content in patients with prostate carcinoma
• Authors: MASAŘÍK, Michal, Jiří SOCHOR, Ondřej ZÍTKA, David HYNEK, Soňa KŘÍŽKOVÁ, Marie STIBOROVÁ, Tomáš ECKSCHLAGER, Vojtěch ADAM and René KIZEK.
• Edition: 15th International Symposium on Molecular Medicine, 2012.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 10600 1.6 Biological sciences
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 1.957
• Organization unit: Faculty of Medicine
• ISSN: 1107-3756
• UT WoS: 000310651600170
• Keywords in English: PSA; prostate cancer; glutathione

Abstract

To detect proste carcinoma, prostatic specific antigen (PSA) is mostly used. However, diagnostics of this tumour disease can become more precise using other types of molecules. In this study, we aimed at detennination of reduced (GSH) and oxidized (GSSG) glutathione, and its ratio, and level of metallothionein in blood of patients with prostate carcinoma. The obtained results were correlated with PSA levels determined in blood of patients. Analyses were petformed in 35 patients with prostate cancer at the age of 54 to 79 years with an average of 66 years and in 8 healthy subjects, who formed the control group. The correlation between PSA and GSH/GSSG reached R2=0.378. The value of PSA and metallothionein content was correlated with R2 = 0.589. However, there were observed large differences between the values of the ratio of GSH and GSSG, which were significantly (P<0.0 1) higher in the control group than in the group of patients with prostate cancer. Also, differences in content between metallothionein control group and a group of patients were highly significant (P<0.01).